Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody.
References:
[1]. WHO Drug Information, Vol. 36, No. 3, 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
Inezetamab is a bispecific anti-CD40 and anti-MSLN IgG1 monoclonal antibody.
References:
[1]. WHO Drug Information, Vol. 36, No. 3, 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.